From: Asthma in the elderly: a double-blind, placebo-controlled study of the effect of montelukast
Age (years, range) | 72.9 ± 4.9, 66–82 |
Sex (F/M) | 16/9 |
BMI | 26.7 ± 5.6 |
Atopy | 20/25 |
Duration of asthma (years) | 35.7 ± 24.8 |
Rhinitis | 18/25 |
Gastroesophageal reflux disease | 9/25 |
Inhaled steroids (dose, range) | 22/25 (388 ± 324, 0–1,000 mcg/day) |
Long –acting bronchodilators | 18/25 |
Anti-cholinergic agents (tiotropium) | 5/25 |
Theophylline | 1/25 |
ACT score | 22.9 ± 2.1 |
Daily asthma symptom score | 0.3 ± 0.6 |
Number of puffs of albuterol per week | 0.8 ± 1.8 |
FEV1% | 81.2 ± 15.8 |
FEV1/FVC | 0.74 ± 0.1 |
FEF25-75% | 78.2 ± 31.5 |
Peripheral blood eosinophils (K/μL) | 0.38 ± 0.25 |
Total serum IgE (IU/ml) | 182 ± 249 |